The Macular Photocoagulation Study (MPS), a multicenter randomized clinical trial that is evaluating photocoagulation for treatment of choroidal neovascularization from age-related macular degeneration (AMD), presumed ocular histoplasmosis, and idiopathic choroidal neovascular membranes, has provided important guidelines for therapy.1-4 One aspect of the study that has received relatively little attention is the interplay between systemic hypertension and choroidal neovascularization. In 1979, when the MPS began enrolling patients, there was no reason to suspect that systemic hypertension would play an important role in the clinical outcomes. Although it was plausible that an increase in intraluminal pressures in choroidal vessels might contribute to visual loss in treated or untreated eyes, there was little or no evidence to support this hypothesis. The study included measurement of blood pressure in all patients. Analysis of the outcomes in patients with and without hypertension has produced some interesting results.
The MPS defined a patient as having
Jampol LM. Hypertension and Visual Outcome in the Macular Photocoagulation Study. Arch Ophthalmol. 1991;109(6):789-790. doi:10.1001/archopht.1991.01080060053022